Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan
Jordan Eye Drug Biosimilar Slashes Costs and Boosts Patient Access
This budget impact analysis from a Jordanian public sector perspective estimates that switching from aflibercept to ranibizumab's biosimilar…
Switching to a biosimilar version of a common eye drug could save Jordan’s public health system millions and help more patients get treatmen…
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
Radiotherapy plus anti-VEGF therapy increases vision loss risk for nAMD
This systematic review and meta-analysis evaluated radiotherapy combined with anti-VEGF therapy versus anti-VEGF monotherapy for neovascular…
Adding radiotherapy to anti-VEGF treatment for wet macular degeneration was linked to a higher risk of vision loss compared to anti-VEGF alo…
Lower vitreous CREG1 levels associated with reduced ranibizumab response in diabetic macular edema
Low CREG1 levels may link to poor treatment response
This retrospective cohort study of 189 patients with diabetic macular edema found that lower vitreous CREG1 levels were associated with non-…
New findings suggest that certain protein levels and blood markers might help identify which patients respond to diabetic macular edema trea…
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy
Adding Laser to Eye Injections Cuts Treatment Burden for Diabetic Eye Disease
This retrospective cohort study included 238 patients with proliferative diabetic retinopathy.
Combining injections with laser treatment for diabetic eye disease significantly reduces future procedures and complications while preservin…
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
How often does scarring develop in treated macular degeneration eyes?
A systematic review and meta-analysis of 58 studies in anti-VEGF-treated nAMD eyes found subretinal fibrosis developed in approximately 10-1…
Scarring in treated macular degeneration eyes affects 10% to 15% within two years and up to half by five years, causing vision loss averagin…
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.